| Primary |
| Product Used For Unknown Indication |
27.1% |
| Prophylaxis |
9.4% |
| Antibiotic Prophylaxis |
6.3% |
| Endocarditis Enterococcal |
5.2% |
| Sepsis |
5.2% |
| Endocarditis |
4.2% |
| Evidence Based Treatment |
4.2% |
| Morganella Infection |
4.2% |
| Premature Birth |
4.2% |
| Agitation |
3.1% |
| Colostomy |
3.1% |
| Convulsion |
3.1% |
| Encephalitis |
3.1% |
| Meningoencephalitis Bacterial |
3.1% |
| Opportunistic Infection Prophylaxis |
3.1% |
| Urinary Tract Infection |
3.1% |
| Acute Tonsillitis |
2.1% |
| Antiretroviral Therapy |
2.1% |
| Appendicitis Perforated |
2.1% |
| Asymptomatic Bacteriuria |
2.1% |
|
| Drug Hypersensitivity |
12.7% |
| Medication Error |
11.1% |
| Stevens-johnson Syndrome |
9.5% |
| Rash Maculo-papular |
6.3% |
| Toxic Epidermal Necrolysis |
6.3% |
| Spina Bifida Cystica |
4.8% |
| Thrombocytopenia |
4.8% |
| Tremor |
4.8% |
| Unresponsive To Stimuli |
4.8% |
| Acute Generalised Exanthematous Pustulosis |
3.2% |
| Anaphylactic Reaction |
3.2% |
| Cholelithiasis |
3.2% |
| Drug Exposure During Pregnancy |
3.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.2% |
| Hypoglycaemia |
3.2% |
| Maternal Exposure During Pregnancy |
3.2% |
| Pancytopenia |
3.2% |
| Phlebitis |
3.2% |
| Pregnancy |
3.2% |
| Pruritus |
3.2% |
|
| Secondary |
| Product Used For Unknown Indication |
28.7% |
| Drug Use For Unknown Indication |
18.3% |
| Ill-defined Disorder |
7.8% |
| Foetal Exposure During Pregnancy |
5.0% |
| Pneumonia |
4.5% |
| Urinary Tract Infection |
3.3% |
| Hypertension |
3.1% |
| Agitation |
2.7% |
| Bacteraemia |
2.7% |
| Enterococcal Infection |
2.5% |
| Infection |
2.5% |
| Staphylococcal Infection |
2.3% |
| Opportunistic Infection Prophylaxis |
2.2% |
| Pyrexia |
2.2% |
| Bacterial Infection |
2.2% |
| Constipation |
2.0% |
| Corynebacterium Infection |
2.0% |
| Enterobacter Infection |
2.0% |
| Streptococcal Infection |
2.0% |
| Candida Infection |
1.7% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
19.3% |
| Drug Hypersensitivity |
10.2% |
| Toxic Epidermal Necrolysis |
10.2% |
| Vomiting |
9.0% |
| Ventricular Extrasystoles |
8.4% |
| Rash |
6.6% |
| Toxicity To Various Agents |
5.4% |
| Urticaria |
3.6% |
| Acute Generalised Exanthematous Pustulosis |
3.0% |
| Rash Maculo-papular |
3.0% |
| Death |
2.4% |
| Premature Baby |
2.4% |
| Premature Separation Of Placenta |
2.4% |
| Renal Failure Chronic |
2.4% |
| Weight Decreased |
2.4% |
| Angioedema |
1.8% |
| Colitis |
1.8% |
| Disseminated Intravascular Coagulation |
1.8% |
| Incorrect Route Of Drug Administration |
1.8% |
| Jarisch-herxheimer Reaction |
1.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.6% |
| Drug Use For Unknown Indication |
18.1% |
| Acne |
8.4% |
| Prophylaxis |
6.3% |
| Depression |
5.0% |
| Pain |
4.5% |
| Hypertension |
4.2% |
| Multiple Myeloma |
4.0% |
| Foetal Exposure During Pregnancy |
2.3% |
| Hiv Infection |
2.2% |
| Drug Exposure During Pregnancy |
2.1% |
| Pneumonia |
2.0% |
| Infection |
2.0% |
| Nausea |
1.9% |
| Sepsis |
1.9% |
| Asthma |
1.8% |
| Anxiety |
1.8% |
| Urinary Tract Infection |
1.7% |
| Constipation |
1.7% |
| Vomiting |
1.5% |
|
| Vomiting |
11.0% |
| Weight Decreased |
10.7% |
| Ventricular Septal Defect |
9.5% |
| Weight Increased |
9.5% |
| Thrombocytopenia |
6.0% |
| Pyrexia |
5.2% |
| Urinary Tract Infection |
5.0% |
| Patent Ductus Arteriosus |
4.7% |
| Pulmonary Haemorrhage |
4.2% |
| Wheezing |
4.2% |
| Respiratory Distress |
3.5% |
| Drug Ineffective |
3.2% |
| Pneumonia |
3.2% |
| Sepsis Neonatal |
3.2% |
| Suicidal Ideation |
3.2% |
| Pulmonary Embolism |
3.0% |
| Renal Impairment |
3.0% |
| Pain |
2.5% |
| Respiratory Failure |
2.5% |
| Sepsis |
2.5% |
|
| Interacting |
| Pneumonia |
59.3% |
| Contraception |
14.8% |
| Cardiac Fibrillation |
11.1% |
| Heart Rate Irregular |
3.7% |
| Infection |
3.7% |
| Micturition Disorder |
3.7% |
| Prostatitis |
3.7% |
|
| Spina Bifida Cystica |
33.3% |
| Strabismus |
33.3% |
| Drug Interaction |
16.7% |
| Urinary Tract Infection |
16.7% |
|
